Available on the company’s SYNCHRON® series chemistry analyzers, the improved benzodiazepine (BNZG) assay from Beckman Coulter Inc provides a rapid screening procedure for determining the concentration of benzodiazepine in human urine at a cutoff value of 200 ng/mL oxazepam. The BNZG reagent features increased sensitivity to benzodiazepine-glucuronide metabolites in urine with the addition of ß-glucuronidase enzyme, which helps remove glucuronides that commonly interfere with the detection of antidepressant drugs.
The prefilled, bar-coded cartridges simplify handling and allow laboratory technologists to track usage, stability calibration frequency, and lot numbers. Meanwhile, the qualitative interpretive report delivers a positive or negative result, eliminating the need for manual interpretation.
Beckman Coulter Inc
(800) 352-3433; www.beckmancoulter.com